Related Experiment Video
Updated: Jan 23, 2026

Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
Published on: May 31, 2024
Impaired frequencies and function of platelets and tissue remodeling in chronic Chagas disease
Claudia Pengue1, Gonzalo Cesar2, María Gabriela Alvarez1
1Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.
Insights
Chronic Trypanosoma cruzi infection causes hemostatic alterations, impacting platelet and coagulation pathways even before cardiac symptoms appear in Chagas disease patients.
Area of Science:
- Immunology
- Cardiovascular Medicine
- Hematology
Background:
- Chronic inflammation from Trypanosoma cruzi infection drives immune system activation in Chagas disease.
- Previous work linked elevated soluble P-selectin to Chagas cardiomyopathy severity.
Purpose of the Study:
- To investigate biomarkers of platelet and endothelial activation, tissue remodeling, and coagulation in chronic Chagas heart disease stages.
- To understand hemostatic changes associated with Trypanosoma cruzi infection.
Main Methods:
- Assessed frequencies of activated platelets (CD41a, CD62P) and adenosine diphosphate-induced platelet activation.
- Measured serum levels of fibrinogen, endothelin-1, and procollagen I in patients across different clinical stages.
- Compared findings between infected subjects and uninfected controls.
Main Results:
- Activated platelet frequencies (CD41a, CD62P) were decreased in T. cruzi-infected patients, inversely correlating with disease severity.
- Platelet activation by adenosine diphosphate was reduced in infected individuals.
- Increased serum fibrinogen was observed in many infected subjects.
- Severe cardiac dysfunction correlated with elevated endothelin-1, while procollagen I levels were normal.
Conclusions:
- Chronic Trypanosoma cruzi infection induces significant hemostatic alterations.
- These alterations occur even in patients without overt cardiac symptoms, suggesting early impact on coagulation and platelet function.
Abstract:
Chronic inflammation, as a consequence of the persistent infection with Trypanosoma cruzi, leads to continuous activation of the immune system in patients with chronic Chagas disease. We have previously shown that increased sera levels of soluble P-selectin are associated with the severity of the cardiomyopathy distinctive of chronic Chagas disease. In this study, we explored the expression of biomarkers of platelet and endothelial activation, tissue remodeling, and mediators of the coagulation cascade in patients at different clinical stages of chronic Chagas heart disease. The frequencies of activated platelets, measured by the expression of CD41a and CD62P were decreased in patients with chronic Chagas disease compared with those in uninfected subjects, with an inverse association with disease severity. Platelet activation in response to adenosine diphosphate was also decreased in T. cruzi-infected subjects. A major proportion of T. cruzi infected subjects showed increased serum levels of fibrinogen. Patients with severe cardiac dysfunction showed increased levels of endothelin-1 and normal values of procollagen I. In conclusion, chronic infection with T. cruzi induced hemostatic alterations, even in those patients who do not yet present cardiac symptoms.
Related Concept Videos
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Kidney Disease I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Chronic Obstructive Pulmonary Disease-I: Introduction

